In a report released today, Rahul Rakhit from LifeSci Capital maintained a Hold rating on Better Therapeutics, Inc. (BTTX – Research Report). The company’s shares closed today at $0.68.
According to TipRanks, Rakhit is an analyst with an average return of -53.4% and a 2.17% success rate. Rakhit covers the Healthcare sector, focusing on stocks such as DarioHealth, Orchestra BioMed Holdings, and Better Therapeutics, Inc..
Currently, the analyst consensus on Better Therapeutics, Inc. is a Moderate Buy with an average price target of $3.00.
See today’s best-performing stocks on TipRanks >>
Based on Better Therapeutics, Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.59 million. In comparison, last year the company had a GAAP net loss of $9.93 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BTTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
- Better Therapeutics price target lowered to $3 from $5 at Lake Street
- Better Therapeutics files to sell 479,516 shares of common stock for holders
- Better Therapeutics reports Q2 EPS (24c), consensus (31c)
- Better Therapeutics issues $6.7M in common stock under its at-the-market program
- Better Therapeutics receives FDA authorization for AspyreRx
